Anti-Infectives: World Market, 2nd. Ed., Vol. I: Antifungals

Table of Contents

CHAPTER ONE: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

CHAPTER TWO: Introduction

• Overview
  • Introduction to Pathogens
  • Antimicrobial Spectrum
  • Bacterial Resistance
  • Principles of Anti-infective Therapy
    • Infecting Organism
    • Antibiotic Sensitivity Testing
    • Site of Infection
    • Host Defenses and Organ Function
    • Antibiotic Pharmcokinetics
    • Monitoring Therapy
  • Combination Therapy and Prophylactic Use
  • Fungal Infections
  • Types of Fungal Infections
    • Superficial
    • Systemic
      • Histoplasmosis
      • Coccidioidomycosis
      • Blastomycosis
    • Demographics and Statistics

CHAPTER THREE: Systemic Antifungal Drugs

• Overview
• Description of Products
  • Allylamines
  • Terbinafine (Lamisil - Novartis)
  • Azoles
  • Fluconazole (Diflucan - Pfizer)
  • Ketoconazole (Nizoral, Johnson & Johnson)
  • Miconazole (Monistat, Johnson & Johnson)
  • Itraconazole (Sporanox, Johnson & Johnson)
  • Posaconazole (Noxafil, Schering-Plough)
  • Virconazole (Vfend, Pfizer)
  • Polyene Macrolides
  • Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
  • Griseofluvin (Fulvicin, Schering)
  • Nystatin (Mycostatin, Westwood Squibb)
  • Miscellaneous Antifungals
  • Flucytosine (Ancoban, Valeant)
  • Echinocandins
• Generic Drug Impact and Availability
• Research and Development
• Market Size and Growth
• Competitive Analysis

CHAPTER FOUR: Topical Antifungal Drugs

• Overview
• Description of Products
  • Allylamines
  • Naftifine (Naftin, Allergan)
  • Terbinafine (Lamisil - Novartis)
  • Butenafine (Mentax, Bertek)
  • Azoles
  • Miconazole (Monistat -Derm, OrthoDermatological)
  • Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
  • Ketoconazole (Nizoral, J&J; Xolegel, Barrier Therapeutics)
  • Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
  • Econazole (Spectazole, Ortho Dermatological)
  • Sulconazole (Exelderm, Westwood-Squibb)
  • Terconazole (Terazol, Ortho Dermatological)
  • Polyene Macrolides
  • Nystatin (Mycostatin, Westwood Squibb)
  • Miscellaneous Antifungals
  • Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
  • Selenium sulfide (Selsun, Chattem Inc)
  • Amorolfine (Loceryl, Roche)
  • Alcortin (Iodoquinol, hydrocortisone, Primus Pharmaceuticals)
• Generic Drug Impact and Availability
• Research and Development
• Market Size and Growth
• Competitive Analysis

CHAPTER FIVE: Issues and Trends Affecting the Antifungal Market

• Introduction
• Fungal Infections and Immunocompromised Patients
• Reimbursement
• Infection Imaging
• Expanded Use of Azoles
• Drug Resistance and Interactions
• Standardized Susceptibility Testing
• Generic Impact and Availability
• Importance of Drug Delivery
• Rx-to-OTC Switches
• The Antifungal Market and Enchiocandins

CHAPTER SIX: Antifungal Drugs: Total Market Size and Forecast

• Overview
• Total market Size and Forecast

CHAPTER SEVEN: Corporate Profiles

• Introduction
• Astellas Pharma Inc
• Barrier Therapeutics, Inc
• Johnson & Johnson Group
• Merck & Company, Inc
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc
• Schering-Plough Corporation

CHAPTER EIGHT: Company Directory

table of exhibits

Chapter One: Executive Summary

• Table 1-1: The World Market for Antifungal Drugs 2004-2011
• Figure 1-1: The World Market for Antifungal Drugs 2004-2011

Chapter Two: Introduction

• Table 2-1: Estimated World and U.S. Incidence of Fungal Infections (thousands)
• Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
• Table 2-2: World Population by Selected Geographical Region, 2006-2050
• Figure 2-2: World Population by Selected Geographical Region, 2006-2050
• Table 2-3: Estimated World Population by Age and Geographical Region, 2006
• Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
• Table 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006
• Figure 2-4: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2006

Chapter Three: Systemic Antifungal Drugs

• Table 3-1: Allylamines
• Table 3-2: Azoles
• Table 3-3: Polyene Macrolides
• Table 3-4: Miscellaneous Antifungals
• Table 3-5: New Generic Drug Approvals for Systemic Antifungals, United States, 2004-2006
• Table 3-6: Systemic Antifungal Drugs in Development
• Table 3-7: The Market for Systemic Antifungal Drugs 2004-2011
• Figure 3-1: Systemic Antifungal Drug Market 2004-2011
• Table 3-8: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2004-2010
• Figure 3-2 : Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2004-2010
• Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2004-2011
• Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2006 and 2011
• Table 3-9: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
• Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2006
• Table 3-10: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
• Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2006
• Table 3-11: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
• Table 3-12: Systemic Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 3-8: Systemic Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
• Table 3-13: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
• Figure 3-9: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Four: Topical Antifungal Drugs

• Table 4-1: Allyamines
• Table 4-2: Topical Azoles
• Table 4-3: Polyene Macrolides
• Table 4-4: Miscellaneous Antifungals
• Table 4-5: New Generic Drug Approvals for Topical Antifungals, United States, 2004-2006
• Table 4-6: Topical Antifungal Drugs in Development
• Table 4-7: Topical Antifungal Drug Market, 2004-2011
• Figure 4-8: Topical Antifungal Drug Market, 2004-2011
• Table 4-8: Topical Antifungal Drug Market, 2004-2011
• Figure 4-9: Topical Antifungal Drug Market by Product Type - Revenues, 2004-2011
• Figure 4-10: Topical Antifungal Drug Market by Product Type -Percent Distribution, 2004-2011
• Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2006 and 2011
• Table 4-9: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2006
• Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2006
• Table 4-10 : Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2006
• Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2006
• Table 4-11: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2006
• Table 4-12: Topical Antifungal Drug Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 4-8: Topical Antifungal Drug Market Projected Market Share by Leading Suppliers 2011
• Table 4-13: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2006
• Figure 4-9: Topical Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2006

Chapter Five: Issues and Trends Affecting the

• Antifungal Market
• Table-5-1: New Generic Drug Approvals for Antifungals, United States, 2004-2006
• Table 5-2: Selected Antifungal Rx-to-OTC Switches

Chapter Six: Antifungal Drugs: Total Market

• Size and Forecast
• Table 6-1: The World Market for Antifungal Drugs 2004-2011
• Figure 6-1: The World Market for Antifungal Drugs 2004-2011
• Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2004-2011
• Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2004-2011
• Figure 6-3: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2006 and 2011